Literature DB >> 2445954

Tetrahydroaminoacridine blocks potassium channels and inhibits sodium inactivation in Myxicola.

C L Schauf1, A Sattin.   

Abstract

In voltage-clamped Myxicola giant axons internally and externally applied tetrahydroaminoacridine (THA) blocked K+ channels with a dissociation constant of 100 microM and slowed their rate of activation. At a concentration of 10 microM, internal THA primarily slowed inactivation of conducting Na+ channels. At 100 microM the decline of the Na+ current during depolarizing pulses was biphasic, with an initial phase 2 to 3 times faster than in control axons. In the presence of THA there was a steady-state inward current accompanied by an increase in amplitude and time constant of Na+ tail currents, as if THA blocked Na+ channels by first entering them and then rendered THA-occluded channels resistant to fast inactivation. THA did not alter activation, prepulse-induced fast inactivation or slow inactivation. The effects of THA on voltage-dependent axonal ion channels might account for central nervous system hyperexcitability seen in some patients treated with THA. Because THA is a potent, centrally active anticholinesterase, even subtle ion channel-directed effects might contribute to its putative antidementia action in clinical states involving a central nervous system deficiency of acetylcholine by selective augmentation of acetylcholine release and/or negation of autoreceptor effects of endogeneous acetylcholine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2445954

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Effects of tacrine, velnacrine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on skeletal neuromuscular transmission in vitro.

Authors:  M F Braga; A L Harvey; E G Rowan
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

Review 2.  Potassium channel blockers and neuronal function.

Authors:  A L Harvey; E G Rowan; A J Anderson
Journal:  Pflugers Arch       Date:  1989       Impact factor: 3.657

3.  The mechanism of tetrahydroaminoacridine-evoked release of endogenous 5-hydroxytryptamine and dopamine from rat brain tissue prisms.

Authors:  T N Robinson; R J De Souza; A J Cross; A R Green
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

4.  Quantitative whole-body autoradiographic determination of tacrine tissue distribution in rats following intravenous or oral dose.

Authors:  W McNally; M Roth; R Young; H Bockbrader; T Chang
Journal:  Pharm Res       Date:  1989-11       Impact factor: 4.200

5.  Comparison of tetrahydroaminoacridine and physostigmine on scopolamine-induced free swim behavior in the rat.

Authors:  C P Dokla; L Rydelek-Fitzgerald
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  High-affinity [3H]THA (tetrahydroaminoacridine) binding sites in rat brain.

Authors:  E E Mena; M C Desai
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

7.  Therapeutic effect of THA on hemicholinium-3-induced learning impairment is independent of serotonergic and noradrenergic systems.

Authors:  J J Hagan; J H Jansen; F E Nefkens; T de Boer
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  The relative potencies of cholinomimetics and muscarinic antagonists on the rat iris in vivo: effects of pH on potency of pirenzepine and telenzepine.

Authors:  J J Hagan; B van der Heijden; C L Broekkamp
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-11       Impact factor: 3.000

9.  Measurements of tacrine and monoamines in brain by in vivo microdialysis argue against release of monoamines by tacrine at therapeutic doses.

Authors:  H A Baldwin; R J De Souza; G S Sarna; T K Murray; A R Green; A J Cross
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

10.  Hemicholinium-3 impairs spatial learning and the deficit is reversed by cholinomimetics.

Authors:  J J Hagan; J H Jansen; C L Broekkamp
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.